Product Overview
Compound: PNC‑27 (p53-derived peptide with HDM-2 binding domain)
Format: Lyophilized Powder (≥97% purity)
Contents: 5 mg per vial
Storage: Store dry below –18 °C. Reconstituted product stable at 2–7 °C for up to 7 days.
For laboratory research only—NOT for human consumption.
Each batch is third-party tested for sequence accuracy and purity. COAs are available on request via providers@theratideusa.com.
PNC‑27 is a synthetic peptide containing residues 12–26 of p53 linked to a cell‑penetrating sequence. It targets HDM‑2 expressed on cancer cell membranes, inducing membrane pores and tumor cell necrosis independent of p53 function :contentReference[oaicite:1]{index=1}.
- Highly selective cytotoxicity against HDM‑2–positive cancer cells, including leukemia lines, with minimal impact on normal cells :contentReference[oaicite:2]{index=2}.
- Demonstrated necrosis in p53-null leukemia cell line K562 via pore formation :contentReference[oaicite:3]{index=3}.
- Confirmed pore formation using immuno-EM studies, showing 1:1 PNC‑27:HDM‑2 complexes :contentReference[oaicite:4]{index=4}.
- Effective against a broad spectrum of tumors—solid and non-solid—in both in vitro and in vivo settings :contentReference[oaicite:5]{index=5}.
Note: All data is preclinical. Not approved for medical use.
In 2017, the FDA issued alerts cautioning consumers against using unauthorized PNC‑27 products due to contamination and unverified claims :contentReference[oaicite:6]{index=6}.
Sold for research only. Not intended for human or animal use, dietary supplement, or therapeutics. Handle only with proper lab protocols. Keep out of reach of children.
FDA Notice: These statements have not been evaluated by the FDA. Not intended to diagnose, treat, cure, or prevent any disease.